MedTrace Logo

Multiple Ascending Dose Study of SPC4955 in Healthy Subjects

NCT01365663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-01-31

No results posted yet for this study

Summary

The purpose of this study is to study safety and tolerability of SPC4955 in healthy subjects.

Conditions

Interventions

DRUG

SPC4955

3 Weekly SC injections

DRUG

SPC4955

3 Weekly SC injections

DRUG

SPC4955

3 Weekly SC injections

DRUG

SPC4955

3 Weekly SC injections

DRUG

SPC4955

3 Weekly SC injections

DRUG

Saline 0.9%

3 Weekly SC injections

Sponsors & Collaborators

  • Santaris Pharma A/S

    lead INDUSTRY

Principal Investigators

  • Werner Feuerer, Dr. med. · Nuvisan GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01365663 on ClinicalTrials.gov